Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Pharma giant targets new standards of care
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
Subscribe To Our Newsletter & Stay Updated
